

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/591,551
--------------------	------------

Filing Date	May 1, 2008
-------------	-------------

First Named Inventor	Darren P. MEDLAND
----------------------	-------------------

Art Unit	1614
----------	------

Examiner Name	Not Yet Assigned
---------------	------------------

Attorney Docket Number	0102286.00167US1
------------------------	------------------

Sheet	1	of	11
-------	---	----	----

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ²
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	EP-0 509 974	10-21-1992	Astra AB		
	BB	EP-0 737 685	10-16-1996	Viaud et al.		
	BC	EP-1 106 621	06-13-2001	Fuji Photo Film Co., Ltd.		
	BD	JP-06 247966-A	09-06-1994	Nisshin Flour Milling Co		
	BE	WO-98/47899	10-29-1998	Ortho-McNeil Corp.		
	BF	WO-99/20624	04-29-1999	Hoffmann-La Roche		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

(Use as many sheets as necessary)

Complete if Known

Attorney Docket Number 0102286.00167US1

Sheet	2	of	11
-------	---	----	----

[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BG	WO-99/21859	05-06-1999	Glaxo Group Limited		
	BH	WO-00/26210	05-11-2000	Merck & Co., Inc.		
	BI	WO-00/64449	11-02-2000	Merck & Co., Inc.		
	BJ	WO-00/35909	06-22-2000	Hoffman-LaRoche		
	BK	WO-00/35921-A1	06-22-2000	F. Hoffman - LaRoche AG		√
	BL	WO-00/56710	09-28-2000	Glaxo Group Limited		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

US1DOCS 6751277v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1> <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/591,551
				Filing Date	May 1, 2008
				First Named Inventor	Darren P. MEDLAND
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	3	of	11	Attorney Docket Number	0102286.00167US1

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ^o
		Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)				
	BM	WO-00/64872	11-02-2000	Vertex Pharmaceuticals Inc.		
	BN	WO-01/12609	02-22-2001	Signal Pharmaceuticals, Inc.		
	BO	WO-01/47922	07-05-2001	Aventis Pharma Limited		
	BP	WO-01/49288	07-12-2001	Merck Frosst Canada & Co.		
	BQ	WO-02/10137	02-07-2002	Signal Pharm. Inc.		
	BR	WO-02/16359	02-28-2002	Glaxo Group Limited		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		
	BY	WO-99/51233	10-14-1999	Merck & Co. Inc.	
	BZ	WO-00/43393	07-27-2000	Merck & Co., Inc.	
	BA1	WO-03/028724	04-10-2003	Smithkline Beecham Corporation	
	BB1	WO-04/016609	02-26-2004	Astrazeneca AB	
	BC1	WO-04/016610	02-26-2004	Astrazeneca AB	
	BD1	WO-00/26211			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and () next to the Cite No. are copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/591,551
				Filing Date	May 1, 2008
				First Named Inventor	Darren P. MEDLAND
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	6	of	11	Attorney Docket Number	0102286.00167US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Adams et al., Bioorg. Med. Chem. Lett. 2001 , 11, 2867-2870.	
	CB	ALAM et al., "Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors; Bioorg Med Chem Lett, Vol. 17, pp. 3463-3467, 2007	
	CC	BUNDGAARD, Design of ProDrugs, Elsevier Science Publishers 1985	
	CD	CAO et al., "Distinct Requirements for p38 α and c-Jun N-terminal Kinase Stress-activated Protein Kinases in Different Forms of Apoptotic Neuronal Death", <i>The Journal of Biological Chemistry</i> , Vol. 279, No. 34, pp. 35903-35913, 20 August 2004	
	CE	CAS Accession No. 2001:432896, Registry Number 344454-31-1	
	CF	CAS Document no. 135:107148	
	CG	CAS document no. 135:43132	
	CH	COREY, E.JR., et. al., "A synthetic Method for Formyl-Ethynyl Conversion (RCHO-RC=CH or RC=CR)", Tetrahedron Letters No. 36, August, 1972.	
	CI	Database Beilstein, Beilstein Institute for Organic Chemistry, Citation No. 5563002 (1987)	
	CJ	DENMARK et al., "Convergence of Mechanistic Pathways in the Palladium(0)-Catalyzed Cross-Coupling of Alkenylsilacyclobutanes and Alkenylsilanols" <i>Organic Letters</i> . Vol. 2, No. 16, pp. 2491-2494. (2000)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/591,551
				Filing Date	May 1, 2008
				First Named Inventor	Darren P. MEDLAND
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	7	of	11	Attorney Docket Number	0102286.00167US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CK	DENMARK et al., "Highly Stereospecific, Palladium-Catalyzed Cross-Coupling of Alkenylsilanols" <i>Organic Letters</i> Vol. 2, No. 4, pp. 565-568 (2000)	
	CL	DHAR, et al., "The TosMIC Approach to 3-(Oxazol-5-yl) Indoles: Application to the Synthesis of Indole-Based IMPDH Inhibitors," <i>Bioorganic & Medicinal Chemistry Letters</i> , 2002.	
	CM	EILERS et al., "Direct Inhibition of c-Jun N-terminal Kinase in Sympathetic Neurons Prevents c-jun Promoter Activation and NGF Withdrawal-induced Death", <i>Journal of Neurochemistry</i> , Vol. 76, pp. 1439-1454, 2001	
	CN	EILERS et al., "Role of the Jun Kinase Pathway in the Regulation of c-Jun Expression and Apoptosis in Sympathetic Neurons", <i>The Journal of Neuroscience</i> , Vol. 18, No. 5, pp. 1713-1724, 1 March 1998	
	CO	ESTUS et al., "Aggregated Amyloid- β Protein Induces Cortical Neuronal Apoptosis and Concomitant "Apoptotic" Pattern of Gene Induction", <i>The Journal of Neuroscience</i> , Vol. 17, No. 20, pp. 7736-7745, 15 October 1997	
	CP	GOLUB et al., <i>Science</i> , Vol. 286, pp. 531-537, 15 Oct 1999	
	CQ	GREENE, T. and Wuts, P., <i>Protective Groups in Organic Synthesis</i> 3rd Edition, Wiley, New York (1999)	
	CR	Guillard, et al. "Synthesis of New Maltonin Analogues from Dimers of Azaindole and Indole by Use of Suzuki Monocoupling", <i>Heterocycles</i> , Vol. 60, No. 4, pp. 865-877 (2003)	
	CS	HAM et al., "A c-Jun Dominant Negative Mutant Protects Sympathetic Neurons against Programmed Cell Death", <i>Neuron</i> , Vol. 14, pp. 927-939, May, 1995	
	CT	Harper and LoGasso, <i>Drugs of the Future</i> 2001, 26, 957-973.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/591,551
				Filing Date	May 1, 2008
				First Named Inventor	Darren P. MEDLAND
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	8	of	11	Attorney Docket Number	0102286.00167US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CU	HARPER et al., "Inhibitors of the JNK Signaling Pathway", <i>Drugs of the Future</i> , Vol. 26, No. 10, pp. 957-973, 2001	
	CV	HATANAKA et al., "Cross-Coupling of Organosilanes with Organic Halides Mediated by Palladium Catalyst and Tris(diethylamino)sulfonium Difluorotrimethylsilicate" <i>J. Org. Chem</i> 53 pp. 918-920 (1988)	
	CW	HATANAKA et al., "Highly Selective Cross-Coupling Reactions of Organosilicon Compounds Mediated by Fluoride Ion and a Palladium Catalyst", <i>Synlett</i> pp. 845-853 (1991)	
	CX	Henry et al, <i>Bioorg. Med. Chem. Lett.</i> 1998, 8, 3335-3340.	
	CY	HOUWING, et al., "Preparation of N-Tosylmethylimino Compounds and their Use in the Synthesis of Oxazoles, Imidazoles and Pyrroles, <i>Tetrahedron Letters</i> No. 2, 1976.	
	CZ	INTERNATIONAL SEARCH REPORT FOR PCT/GB2004/002099, mailed 02 December 2004, 4 pages	
	CA1	INTERNATIONAL SEARCH REPORT for PCT/GB2005/000779, mailed 12 August 2005, 4 pages	
	CB1	KRASNOKUTSKAYA et al., <i>Khim. Geterotsikl. Soed</i> No. 3 pp. 380-384 (1977)	
	CC1	KRUBER, <i>Caplus</i> , Copyright 2007 ACS on STN, 2 pages	
	CD1	Kumar et al, "Synthesis of 7-Azaindole and 7-Azaoxindole Derivatives through a Palladium-Catalyzed Cross Coupling Reaction", <i>J. Org. Chem</i> , 57, pp. 6995-6998 (1992)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/591,551
				Filing Date	May 1, 2008
				First Named Inventor	Darren P. MEDLAND
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	9	of	11	Attorney Docket Number	0102286.00167US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CE1	LECOINTE, "Reach-through Claims", International Pharmaceutical (2002)(also available at < http://www.bakerbotts.com/infocenter/publications/detail.aspx?id=bffe4a7d-5beb-4cf8-a189-15a190f0eb >)	
	CF1	LISNOCK et al., "Activation of JNK3 α 1 Requires Both MKK4 and MKK7: Kinetic Characterization of in Vitro Phosphorylated JNK3 α 1", <i>Biochemistry</i> , Vol. 39, pp. 3141-3149, 2000	
	CG1	LITTKE et al., "Pd/P(t-Bu) ₃ : A Mild and General Catalyst for Stille Reactions of Aryl Chlorides and Aryl Bromides" <i>J. Am. Chem. Soc.</i> 124 pp. 6343-6348 (2002)	
	CH1	LITTKE et al., "Versatile Catalysts for the Suzuki Cross-Coupling of Arylboronic Acids with Aryl and Vinyl Halides and Triflates under Mild Conditions" <i>J. Am. Chem. Soc.</i> 122 pp. 4020-4028 (2000)	
	CI1	MARTIN et al., "Palladium-Catalyzed Cross-Coupling Reactions of Organoboronic Acids with Organic Electrophiles" <i>Acta Chemica Scandinavica</i> 47, pp. 221-230 (1993)	
	CJ1	MEROUR et al., "Synthesis and Reactivity of 7-Azaindoles (1H-Pyrrolo[2,3-b]pyridine) <i>Current Organic Chemistry</i> 5 pp. 471-506 (2001)	
	CK1	Mettey, et al., "Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity and Cellular Effects", <i>J. Med. Chem.</i> 46, pp. 222-236 (2003)	
	CL1	MITCHELL, T. "Palladium-Catalysed Reactions of Organotin Compounds" <i>Synthesis</i> pp. 803-815 (1992)	
	CM1	Park et al., "A Facile Synthesis of 2,3-Disubstitute Pyrrolo[2,3-b]pyridines via Palladium-Catalyzed Heteroannulation with Internal Alkynes", <i>Tetrahedron Letters</i> 39, pp. 627-630 (1998)	
	CN1	Pisano et al., "Bis-indols: a Novel Class of Molecules Enhancing the Cytodifferentiating Properties of Retinoids in Myeloid Leukemia Cells", <i>Blood</i> , Vol. 100, No. 10, pp. 3719-3730 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/591,551
				Filing Date	May 1, 2008
				First Named Inventor	Darren P. MEDLAND
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	10	of	11	Attorney Docket Number	0102286.00167US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CO1	RESNICK, et al. "Targeting JNK3 for the Treatment of Neurodegenerative Disorders", Drug Discovery Today, Elsevier Science LTD. 9:21 (2004) pp. 932-939	
	CP1	SILVA, "Reach through Claims: Bust or Boon?", Intellectual Property Update (available at < http://www.dorsey.com/publications/legal_detail.aspx?FlashNavID=pubs_legal&pubid=170565003 >)	
	CQ1	SMULIK AND DIVER, "Synthesis of Cyclosporin A-Derived Affinity Reagents by Olefin Metathesis", Organic Letters, Vol. 4, No. 12, pp. 2051-2054, 2002	
	CR1	STILLE, J.K., "The Palladium-Catalyzed Cross-Coupling Reactions of Organotin REagents with Organic Electrophiles" <i>Angew. Chem. Int. Ed. Engl.</i> 25 pp. 508-524 (1986)	
	CS1	SUZUKI, A. "Synthetic Studies via the Cross-Coupling REaction of Organoboron Derivatives with Organic Halides" <i>Pure Appl. Chem</i> Vol. 63, No. 3 pp. 419-422 (1991)	
	CT1	TAMAO et al., "Palladium-Catalyzed Cross-Coupling REaction of Alkenylalkoxysilanes with Aryl and Alkenyl Halides in the Presence of a Fluoride Ion" <i>Tetrahedron Letters</i> , Vol. 30, No. 44 pp. 6051-6054 (1989)	
	CU1	TAYLOR et al., "Intramolecular Diels-Alder Reactions of 1,2,4-Triazines" <i>Tetrahedron</i> , Vol. 43, NO. 21 pp. 5145-5158 (1987)	
	CV1	VAN LEUSEN, et al., "Chapter 3: Synthetic Uses of Tosylmethyl Isocyanide (TosMIC), Organic Reactions, Vol. 57, 2001.	
	CW1	VIPPAGUNTA et al., "Crystalline Solids", Advanced Drug Delivery Reviews, Vol. 48, No. 1; pp. 3-26, 2001	
	CX1	WATSON et al., "Phosphorylation of c-Jun is Necessary for Apoptosis Induced by Survival Signal Withdrawal in Cerebellar Granule Neurons", <i>The Journal of Neuroscience</i> , Vol. 18, No. 2, pp. 751-762, 15 January 1998	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/591,551
				Filing Date	May 1, 2008
				First Named Inventor	Darren P. MEDLAND
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	11	of	11	Attorney Docket Number	0102286.00167US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CY1	WEST, Anthony R., "Solid State Chemistry and its Applications", Wiley, NY 1988	
	CZ1	Witherington et al., "5-Aryl-pyrazolo [3,4-b]pyridines: Potent Inhibitors of Glycogen Synthase Kinase-3 (GSK-3)", Bioorganic & Medicinal Chemistry Letters 13, pp. 1577-1580 (2003)	
	CA2	YOUNG et al., "Pyridinyl Imidazole Inhibitors of p38 Mitogen-activated Protein Kinase Bind in the ATP Site", <i>The Journal of Biological Chemistry</i> , Vol. 272, No. 18, pp. 12116-12121, 2 May 1997	
	CB2	ZEVACO, T. et al., 'Bismuth (III) Pyridine - and Pyrazine-Carboxylates', <i>New J. Chem.</i> , Vol. 15, pp. 927-930, 1991	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.